Pharmaceutical Technology

JULY 2, 2025

Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Historically, this erodes the market dominance held by the branded drug.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 4, 2025

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

We may still continue to send you service-related and other non-promotional communications. How will RFK Jr’s American dream for vaccines play out? By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy.

Hospitals 52

Hospitals Insurance Coverage and Processing Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out? Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Sign up for our daily news round-up!

Packaging 52

Packaging Drug Development Drug Pricing Biosimilars 52

pharmaphorum

JUNE 17, 2025

. … So if we can reduce some of the unnecessary cost and time of the six to 15 months toxicity and animal testing period, we can lower barriers to entry, we can lower R&D costs, and we can ideally lower drug prices, which is a big goal for this administration.” Sometimes they didnt talk. Each centre was autonomous.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmaceutical Technology

JULY 10, 2025

Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. The partnership will enhance the availability of the affordable biosimilar on a global scale. The biosimilar is a recombinant humanised antibody Fab’ fragment targeting TNFα, conjugated to a 40kDa polyethylene glycol.

Biosimilars 52

Biosimilars Packaging Hospitals Communication 52

Pharmaceutical Technology

JULY 4, 2025

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). The drug addresses bone loss due to hormone ablation therapy in men with prostate cancer and is used in long-term systemic glucocorticoid therapy in adults.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. How will RFK Jr’s American dream for vaccines play out?

Packaging 52

Packaging Adverse Reactions Communication Hospitals 52

Pharmaceutical Technology

JULY 11, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Bevacizumab Biosimilar in Endometrial Cancer Reports LOA and PTSR Model - Iparomlimab + Tuvonralimab in Nasopharyngeal C. How will RFK Jr’s American dream for vaccines play out? Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Hospitals Biosimilars Communication 52

Pharmaceutical Technology

JULY 7, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. How will RFK Jr’s American dream for vaccines play out?

Labelling 52

Labelling Packaging Communication Hospitals 52

Pharmaceutical Commerce

JULY 1, 2025

Access represents handling social needs for patients that can affect their ability to benefit from CGT treatment, including housing, transportation, housing, and communication needs. Equitable geographic distribution of treatment centers are also a priority.

Insurance Coverage and Processing 64

Insurance Coverage and Processing Drug Pricing Biosimilars Communication 64

Pharmaceutical Technology

JUNE 27, 2025

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59

Pharmaceutical Technology

JUNE 2, 2023

In a bit to challenge the market dominance of AbbVie’s Humira (adalimumab), the online pharmacy Cost Plus Drugs, owned by billionaire Mark Cuban has announced a plan to market Coherus Biosciences’ biosimilar Yusimry (adalimumab-aqvh), Cost Plus Drugs will be offering Yusimry at $569 per unit, excluding shipping and dispensing charges.

Biosimilars 52

Biosimilars Online Pharmacies Drug Pricing Communication 52

Big Molecule Watch

JANUARY 10, 2025

As 2025 begins, we would like to reflect on last years regulatory developments in the biologics and biosimilars space. There were also 18 FDA approvals of biosimilar products , including 6 ustekinumab biosimilars and 5 aflibercept biosimilars in 2024 alone. Here are some of the top regulatory developments from 2024.

Biosimilars 45

Biosimilars Drug Pricing Labelling Communication 45

Pharmaceutical Technology

DECEMBER 9, 2022

There are also strict price controls, which in some cases can limit profitability for manufacturers. Brazilian public spending on healthcare, drug pricing reforms and remote medicine. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. “Patent losses could sink Allergan”.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52

Putting Patients First Blog

JANUARY 27, 2025

This includes clear communication about how AI tools are used in clinical and administrative Transparency fosters trust and empowers patients and providers to actively participate in care decisions. 38 Furthermore, CMS should include manufacturer rebates in the definition of “negotiated price.”

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

FDA Law Blog: Biosimilars

MAY 13, 2025

Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. Of interest to these bloggers is the provision that deals with personal use importation. (We Please bear with us.)

Online Pharmacies 59

Online Pharmacies Drug Pricing Documentation Pharmaceutical Manufacturing 59

FDA Law Blog: Biosimilars

MAY 12, 2025

It sets forth three directives: HHS shall consider facilitating direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation (MFN) price. by November 12), if significant progress toward MFN pricing is not made, HHS must propose a regulation to impose it.

Department of Veterans Affairs 77

Department of Veterans Affairs Drug Pricing Pharmaceutical Manufacturing Biosimilars 77

FDA Law Blog: Biosimilars

MAY 21, 2025

Kirschenbaum Following up on Donald Trumps May 12 Executive Order on Most Favored Nation Prescription Drug Pricing (see our post here ), The Department of Health and Human Services today issued a brief press release answering two of the multitude of questions raised by the Executive Order. To be continued.

Biosimilars 59

Biosimilars Communication Pharmaceutical Manufacturing Drug Pricing 59